Free Trial

Immutep (NASDAQ:IMMP) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?

Immutep logo with Medical background

Immutep Limited (NASDAQ:IMMP - Get Free Report)'s stock price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.04 and traded as low as $1.95. Immutep shares last traded at $1.95, with a volume of 33,160 shares trading hands.

Analyst Ratings Changes

Separately, Robert W. Baird boosted their price objective on Immutep from $6.00 to $7.00 and gave the company an "outperform" rating in a research note on Friday, November 15th.

Read Our Latest Research Report on IMMP

Immutep Stock Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25. The business has a 50 day moving average of $2.04 and a 200-day moving average of $2.10.

Hedge Funds Weigh In On Immutep

A number of institutional investors have recently added to or reduced their stakes in IMMP. Fortitude Advisory Group L.L.C. bought a new position in shares of Immutep during the 4th quarter valued at about $28,000. ABC Arbitrage SA bought a new position in shares of Immutep during the 4th quarter valued at about $152,000. XY Capital Ltd increased its position in shares of Immutep by 108.3% during the 3rd quarter. XY Capital Ltd now owns 108,349 shares of the biotechnology company's stock valued at $239,000 after purchasing an additional 56,344 shares during the last quarter. Finally, Meridian Wealth Management LLC increased its position in shares of Immutep by 4.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company's stock valued at $881,000 after purchasing an additional 17,250 shares during the last quarter. 2.32% of the stock is currently owned by institutional investors.

About Immutep

(Get Free Report)

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

Featured Articles

Should You Invest $1,000 in Immutep Right Now?

Before you consider Immutep, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.

While Immutep currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines